Clinical and genetic characteristics of long QT syndrome;Clínica y genética en el síndrome de QT largo

Revista Espanola de Cardiologia

Volumn 60, Issue 7, 2007, Pages 739-752

  Medeiros Domingo, Argelia ^a,c   Iturralde Torres, Pedro ^b   Ackerman, Michael J ^c  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^c Mayo Clinic   (United States)

Author keywords

Arrhythmias; Cardiac arrest; Gene mutation; Long QT syndrome; Sudden death; Syncope; Torsade de pointes

Indexed keywords

ATENOLOL; METOPROLOL; NADOLOL; PROPANOL;

CLINICAL FEATURE; DNA POLYMORPHISM; ELECTROCARDIOGRAPHY; GENE MUTATION; GENETIC TRAIT; HEART DEATH; HEART VENTRICLE ARRHYTHMIA; HUMAN; LONG QT SYNDROME; QT INTERVAL; REPOLARIZATION; REVIEW; TORSADE DES POINTES; CLASSIFICATION; GENETICS;

HUMANS; LONG QT SYNDROME;

EID: 34548019935     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1157/13108280     Document Type: Review

References (127)

1. Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J. 1957;54:59-68.
2. Romano C, Gemme G, Pongiglione R. Rare cardiac arrhythmias of the pediatric age. I. Repetitive paroxysmal tachycardia. Minerva Pediatr. 1963;15:1155-64.
3. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 1995;80:795-803.
4. Wang Q, Shen J, Li Z, Timothy K, Vincent GM, Priori SG, et al. Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia. Hum Mol Genet. 1995;4:1603-7.
5. Ackerman MJ. The long QT syndrome: ion channel diseases of the heart. Mayo Clin Proc. 1998;73:250-69.
6. Priori SG. Inherited arrhythmogenic diseases: the complexity beyond monogenic disorders. Circ Res. 2004;94:140-5.
7. Tester DJ, Will ML, Haglund CM, Ackerman MJ. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart Rhythm. 2005;2:507-17.
8. Napolitano C, Priori SG, Schwartz PJ, Bloise R, Ronchetti E, Nastoli J, et al. Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. JAMA. 2005;294:2975-80.
9. Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: clinical impact. Circulation. 1999;99:529-33.
10. Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 2001;103:89-95.
11. Ackerman MJ, Tester DJ, Porter CJ. Swimming, a gene-specific arrhythmogenic trigger for inherited long QT syndrome. Mayo Clin Proc. 1999;74:1088-94.
12. Zhang L, Timothy KW, Vincent GM, Lehmann MH, Fox J, Giuli LC, et al. Spectrum of ST-T-wave patterns and repolarization parameters in congenital long-QT syndrome: ECG findings identify genotypes. Circulation. 2000;102:2849-55.
13. Zareba W. Genotype-specific ECG patterns in long QT syndrome. J Electrocardiol. 2006;39:S101-6.
14. Khositseth A, Tester DJ, Will ML, Bell CM, Ackerman MJ. Identification of a common genetic substrate underlying postpartum cardiac events in congenital long QT syndrome. Heart Rhythm. 2004;1:60-4.
15. Beaufort-Krol GC, Van den Berg MP, Wilde AA, Van Tintelen JP, Viersma JW, Bezzina CR, et al. Developmental aspects of long QT syndrome type 3 and Brugada syndrome on the basis of a single SCN5A mutation in childhood. J Am Coll Cardiol. 2005;46:331-7.
16. Mohler PJ, Schott JJ, Gramolini AO, Dilly KW, Guatimosim S, du-Bell WH, et al. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature. 2003;421:634-9.
17. Mohler PJ, Bennett V. Ankyrin-based cardiac arrhythmias: a new class of channelopathies due to loss of cellular targeting. Curr Opin Cardiol. 2005;20:189-93.
18. Mohler PJ, Splawski I, Napolitano C, Bottelli G, Sharpe L, Timothy K, et al. A cardiac arrhythmia syndrome caused by loss of ankyrin-B function. Proc Natl Acad Sci USA. 2004;101:9137-42.
19. Splawski I, Tristani-Firouzi M, Lehmann MH, Sanguinetti MC, Keating MT. Mutations in the hminK gene cause long QT syndrome and suppress IKs function. Nat Genet. 1997;17:338-40.
20. Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW, et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell. 1999;97:175-87.
21. Andersen ED, Krasilnikoff PA, Overvad H. Intermittent muscular weakness, extrasystoles, and multiple developmental anomalies. A new syndrome? Acta Paediatr Scand. 1971;60:559-64.
22. Tawil R, Ptacek LJ, Pavlakis SG, DeVivo DC, Penn AS, Ozdemir C, et al. Andersen's syndrome: potassium-sensitive periodic paralysis, ventricular ectopy, and dysmorphic features. Ann Neurol. 1994;35:326-30.
23. Plaster NM, Tawil R, Tristani-Firouzi M, Canun S, Bendahhou S, Tsunoda A, et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell. 2001;105:511-9.
24. Zhang L, Benson DW, Tristani-Firouzi M, Ptacek LJ, Tawil R, Schwartz PJ, et al. Electrocardiographic features in Andersen-Tawil syndrome patients with KCNJ2 mutations: characteristic T-U-wave patterns predict the KCNJ2 genotype. Circulation. 2005;111:2720-6.
25. Yoon G, Oberoi S, Tristani-Firouzi M, Etheridge SP, Quitania L, Kramer JH, et al. Andersen-Tawil syndrome: Prospective cohort analysis and expansion of the phenotype. Am J Med Genet A. 2006;140:312-21.
26. Splawski I, Timothy KW, Sharpe LM, Decher N, Kumar P, Bloise R, et al. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell. 2004;119:19-31.
27. Splawski I, Timothy KW, Decher N, Kumar P, Sachse FB, Beggs AH, et al. Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc Natl Acad Sci USA. 2005;102:8089-96.
28. Vatta M, Ackerman M, Ye B, Makielski J, Ughanze E, Taylor E, et al. Mutant Caveolin-3 induces persistent late sodium current and is associated with long QT syndrome. Circulation. 2006. En prensa.
29. Medeiros A, Kaku T, Tester DJ, Iturralde P, Itty A, Ye B, et al. Sodium channel B4 subunit mutation causes congenital long QT syndrome. Heart Rhythm 2006;3:S34.
30. Neyroud N, Tesson F, Denjoy I, Leibovici M, Donger C, Barhanin J, et al. A novel mutation in the potassium channel gene KVLQT1 causes the Jervell and Lange-Nielsen cardioauditory syndrome. Nat Genet. 1997;15:186-9.
31. Schwartz PJ, Spazzolini C, Crotti L, Bathen J, Amlie JP, Timothy K, et al. The Jervell and Lange-Nielsen Syndrome. natural history, molecular basis, and clinical outcome. Circulation. 2006.
32. Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long QT syndrome. An update. Circulation. 1993;88:782-4.
33. Chang IK, Shyu MK, Lee CN, Kau ML, Ko YH, Chow SN, et al. Prenatal diagnosis and treatment of fetal long QT syndrome: a case report. Prenat Diagn. 2002;22:1209-12.
34. Zhao H, Strasburger JF, Cuneo BF, Wakai RT. Fetal cardiac repolarization abnormalities. Am J Cardiol. 2006;98:491-6.
35. Miller TE, Estrella E, Myerburg RJ, Garcia de Viera J, Moreno N, Rusconi P, et al. Recurrent third-trimester fetal loss and maternal mosaicism for long-QT syndrome. Circulation. 2004;109:3029-34.
36. Tester DJ, McCormack J, Ackerman MJ. Prenatal molecular genetic diagnosis of congenital long QT syndrome by strategic genotyping. Am J Cardiol. 2004;93:788-91.
37. Cowan JC, Yusoff K, Moore M, Amos PA, Gold AE, Bourke JP, et al. Importance of lead selection in QT interval measurement. Am J Cardiol. 1988;61:83-7.
38. Monnig G, Eckardt L, Wedekind H, Haverkamp W, Gerss J, Milberg P, et al. Electrocardiographic risk stratification in families with congenital long QT syndrome. Eur Heart J. 2006.
39. Bazett H. An analysis of the time-relations of electrocardiograms. Heart. 1920;7:353-70.
40. Viskin S, Rosovski U, Sands AJ, Chen E, Kistler PM, Kalman JM, et al. Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one. Heart Rhythm. 2005;2:569-74.
41. Vincent GM, Timothy KW, Leppert M, Keating M. The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. N Engl J Med. 1992;327:846-52.
42. Perkiomaki JS, Zareba W, Nomura A, Andrews M, Kaufman ES, Moss AJ. Repolarization dynamics in patients with long QT syndrome. J Cardiovasc Electrophysiol. 2002;13:651-6.
43. Zareba W, Moss AJ, Le Cessie S, Hall WJ. T wave alternans in idiopathic long QT syndrome. J Am Coll Cardiol. 1994;23:1541-6.
44. Narayan SM. T-wave alternans and the susceptibility to ventricular arrhythmias. J Am Coll Cardiol. 2006;47:269-81.
45. Beinder E, Grancay T, Menendez T, Singer H, Hofbeck M. Fetal sinus bradycardia and the long QT syndrome. Am J Obstet Gynecol. 2001;185:743-7.
46. Lupoglazoff JM, Denjoy I, Villain E, Fressart V, Simon F, Bozio A, et al. Long QT syndrome in neonates: conduction disorders associated with HERG mutations and sinus bradycardia with KCNQ1 mutations. J Am Coll Cardiol. 2004;43:826-30.
47. Scott WA, Dick M 2nd. Two:one atrioventricular block in infants with congenital long QT syndrome. Am J Cardiol. 1987;60:1409-10.
48. Garson A Jr, Dick M 2nd, Fournier A, Gillette PC, Hamilton R, Kugler JD, et al. The long QT syndrome in children. An international study of 287 patients. Circulation. 1993;87:1866-72.
49. Trippel DL, Parsons MK, Gillette PC. Infants with long-QT syndrome and 2:1 atrioventricular block. Am Heart J. 1995;130:1130-4.
50. Gorgels AP, Al Fadley F, Zaman L, Kantoch MJ, Al Halees Z. The long QT syndrome with impaired atrioventricular conduction: a malignant variant in infants. J Cardiovasc Electrophysiol. 1998;9:1225-32.
51. Van Hare GF, Franz MR, Roge C, Scheinman MM. Persistent functional atrioventricular block in two patients with prolonged QT intervals: elucidation of the mechanism of block. Pacing Clin Electrophysiol. 1990;13:608-18.
52. Lupoglazoff JM, Cheav T, Baroudi G, Berthet M, Denjoy I, Cauchemez B, et al. Homozygous SCN5A mutation in long-QT syndrome with functional two-to-one atrioventricular block. Circ Res. 2001;89:E16-21.
53. Hoorntje T, Alders M, Van Tintelen P, Van der Lip K, Sreeram N, Van der Wal A, et al. Homozygous premature truncation of the HERG protein: the human HERG knockout. Circulation. 1999;100:1264-7.
54. Piippo K, Laitinen P, Swan H, Toivonen L, Viitasalo M, Pasternack M, et al. Homozygosity for a HERG potassium channel mutation causes a severe form of long QT syndrome: identification of an apparent founder mutation in the Finns. J Am Coll Cardiol. 2000;35:1919-25.
55. Medeiros D, Argelia TK, Tester DJ, Iturralde Torres P, Itty A, et al. Sodium channel? Subunit mutation causes congenital long QT syndrome. Heart Rhythm 2006;3:S34.
56. Noda T, Shimizu W, Satomi K, Suyama K, Kurita T, Aihara N, et al. Classification and mechanism of Torsade de Pointes initiation in patients with congenital long QT syndrome. Eur Heart J. 2004;25:2149-54.
57. Liu J, Laurita KR. The mechanism of pause-induced torsade de pointes in long QT syndrome. J Cardiovasc Electrophysiol. 2005;16:981-7.
58. Viskin S, Fish R, Zeltser D, Belhassen B, Heller K, Brosh D, et al. Arrhythmias in the congenital long QT syndrome: how often is torsade de pointes pause dependent? Heart. 2000;83:661-6.
59. Walker BD, Krahn AD, Klein GJ, Skanes AC, Yee R. Burst bicycle exercise facilitates diagnosis of latent long QT syndrome. Am Heart J. 2005;150:1059-63.
60. Vincent GM, Jaiswal D, Timothy KW. Effects of exercise on heart rate, QT, QTc and QT/QS2 in the Romano-Ward inherited long QT syndrome. Am J Cardiol. 1991;68:498-503.
61. Takenaka K, Ai T, Shimizu W, Kobori A, Ninomiya T, Otani H, et al. Exercise stress test amplifies genotype-phenotype correlation in the LQT1 and LQT2 forms of the long-QT syndrome. Circulation. 2003;107:838-44.
62. Swan H, Viitasalo M, Piippo K, Laitinen P, Kontula K, Toivonen L. Sinus node function and ventricular repolarization during exercise stress test in long QT syndrome patients with KvLQT1 and HERG potassium channel defects. J Am Coll Cardiol. 1999;34:823-9.
63. Schwartz PJ, Priori SG, Locati EH, Napolitano C, Cantu F, Towbin JA, et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation. 1995;92:3381-6.
64. Shimizu W. The long QT syndrome: therapeutic implications of a genetic diagnosis. Cardiovasc Res. 2005;67:347-56.
65. Crozier IG, Loughnan A, Dow LJ, Low CJ, Ikram H. Congenital long QT syndrome in adults. N Z Med J. 1989;102:340-1.
66. Moss AJ, Zareba W, Kaufman ES, Gartman E, Peterson DR, Benhorin J, et al. Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-gogo-related gene potassium channel. Circulation. 2002;105:794-9.
67. Di Paolo M, Luchini D, Bloise R, Priori SG. Postmortem molecular analysis in victims of sudden unexplained death. Am J Forensic Med Pathol. 2004;25:182-4.
68. Ackerman MJ, Tester DJ, Porter CJ, Edwards WD. Molecular diagnosis of the inherited long-QT syndrome in a woman who died after near-drowning. N Engl J Med. 1999;341:1121-5.
69. Chugh SS, Senashova O, Watts A, Tran PT, Zhou Z, Gong Q, et al. Postmortem molecular screening in unexplained sudden death. J Am Coll Cardiol. 2004;43:1625-9.
70. Tester DJ, Ackerman MJ. The role of molecular autopsy in unexplained sudden cardiac death. Curr Opin Cardiol. 2006;21:166-72.
71. Tester DJ, Ackerman MJ. Postmortem long QT syndrome genetic testing for sudden unexplained death in the young. J Am Coll Cardiol. 2007;49:240-6.
72. Arnestad M, Crotti L, Rognum TO, Insolia R, Pedrazzini M, Ferrandi C, et al. Prevalence of long-QT syndrome gene variants in sudden infant death syndrome. Circulation. 2007;115:361-7.
73. Schwartz PJ. Pro: newborn ECG screening to prevent sudden cardiac death. Heart Rhythm. 2006;3:1353-5.
74. Quaglini S, Rognoni C, Spazzolini C, Priori SG, Mannarino S, Schwartz PJ. Cost-effectiveness of neonatal ECG screening for the long QT syndrome. Eur Heart J. 2006;27:1824-32.
75. Gouas L, Nicaud V, Berthet M, Forhan A, Tiret L, Balkau B, et al. Association of KCNQ1, KCNE1, KCNH2 and SCN5A polymorphisms with QTc interval length in a healthy population. Eur J Hum Genet. 2005;13:1213-22.
76. Niu DM, Hwang B, Hwang HW, Wang NH, Wu JY, Lee PC, et al. A common SCN5A polymorphism attenuates a severe cardiac phenotype caused by a nonsense SCN5A mutation in a chinese family with an inherited cardiac conduction defect. J Med Genet. 2006. En prensa.
77. Poelzing S, Forleo C, Samodell M, Dudash L, Sorrentino S, Anaclerio M, et al. SCN5A polymorphism restores trafficking of a Brugada syndrome mutation on a separate gene. Circulation. 2006;114:368-76.
78. Crotti L, Lundquist AL, Insolia R, Pedrazzini M, Ferrandi C, De Ferrari GM, et al. KCNH2-K897T is a genetic modifier of latent congenital long-QT syndrome. Circulation. 2005;112:1251-8.
79. Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC, et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation. 2002;105:1943-8.
80. Plant LD, Bowers PN, Liu Q, Morgan T, Zhang T, State MW, et al. A common cardiac sodium channel variant associated with sudden infant death in African Americans, SCN5A S1103Y. J Clin Invest. 2006;116:430-5.
81. Makielski JC, Ye B, Valdivia CR, Pagel MD, Pu J, Tester DJ, et al. A ubiquitous splice variant and a common polymorphism affect heterologous expression of recombinant human SCN5A heart sodium channels. Circ Res. 2003;93:821-8.
82. Tan BH, Valdivia CR, Rok BA, Ye B, Ruwaldt KM, Tester DJ, et al. Common human SCN5A polymorphisms have altered electrophysiology when expressed in Q1077 splice variants. Heart Rhythm. 2005;2:741-7.
83. Ackerman MJ, Khositseth A, Tester DJ, Hejlik JB, Shen WK, Porter CB. Epinephrine-induced QT interval prolongation: a gene-specific paradoxical response in congenital long QT syndrome. Mayo Clin Proc. 2002;77:413-21.
84. Khositseth A, Hejlik J, Shen WK, Ackerman MJ. Epinephrine-induced T-wave notching in congenital long QT syndrome. Heart Rhythm. 2005;2:141-6.
85. Shimizu W, Noda T, Takaki H, Nagaya N, Satomi K, Kurita T, et al. Diagnostic value of epinephrine test for genotyping LQT1, LQT2, and LQT3 forms of congenital long QT syndrome. Heart Rhythm. 2004;1:276-83.
86. Vyas H, Hejlik J, Ackerman MJ. Epinephrine QT stress testing in the evaluation of congenital long-QT syndrome: diagnostic accuracy of the paradoxical QT response. Circulation. 2006;113:1385-92.
87. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013-22.
88. Viskin S, Justo D, Halkin A, Zeltser D. Long QT syndrome caused by noncardiac drugs. Prog Cardiovasc Dis. 2003;45:415-27.
89. Fitzgerald PT, Ackerman MJ. Drug-induced torsades de pointes: the evolving role of pharmacogenetics. Heart Rhythm. 2005;2:S30-7.
90. Roden DM. Long QT syndrome: reduced repolarization reserve and the genetic link. J Intern Med. 2006;259:59-69.
91. Abriel H, Schlapfer J, Keller DI, Gavillet B, Buclin T, Biollaz J, et al. Molecular and clinical determinants of drug-induced long QT syndrome: an iatrogenic channelopathy. Swiss Med Wkly. 2004;134:685-94.
92. Sun Z, Milos PM, Thompson JF, Lloyd DB, Mank-Seymour A, Richmond J, et al. Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced torsades de pointes. J Mol Cell Cardiol. 2004;37:1031-9.
93. Ackerman MJ, Tester DJ, Jones GS, Will ML, Burrow CR, Curran ME. Ethnic differences in cardiac potassium channel variants: implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome. Mayo Clin Proc. 2003;78:1479-87.
94. Ackerman MJ, Splawski I, Makielski JC, Tester DJ, Will ML, Timothy KW, et al. Spectrum and prevalence of cardiac sodium channel variants among black, white, Asian, and Hispanic individuals: implications for arrhythmogenic susceptibility and Brugada/ long QT syndrome genetic testing. Heart Rhythm. 2004;1:600-7.
95. Ye B, Valdivia CR, Ackerman MJ, Makielski JC. A common human SCN5A polymorphism modifies expression of an arrhythmia causing mutation. Physiol Genomics. 2003;12:187-93.
96. Seth R, Moss AJ, McNitt S, Zareba W, Andrews ML, Qi M, et al. Long QT syndrome and pregnancy. J Am Coll Cardiol. 2007;49:1092-8.
97. Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, et al. Risk stratification in the long-QT syndrome. N Engl J Med. 2003;348:1866-74.
98. Locati EH, Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Lehmann MH, et al. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. Circulation. 1998;97:2237-44.
99. Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Robinson JL, Priori SG, et al. Influence of genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. N Engl J Med. 1998;339:960-5.
100. Hobbs J, Peterson D, Moss A, McNitt S, Zareba W, Goldenberg I, et al. Risk of aborted cardiac arrest or sudden death during adolescence in the long-QT syndrome JAMA. 2006. En prensa.
101. Schwartz PJ. The congenital long QT syndromes from genotype to phenotype: clinical implications. J Intern Med. 2006;259:39-47.
102. Itoh T, Kikuchi K, Odagawa Y, Takata S, Yano K, Okada S, et al. Correlation of genetic etiology with response to beta-adrenergic blockade among symptomatic patients with familial long-QT syndrome. J Hum Genet. 2001;46:38-40.
103. Shimizu W, Tanabe Y, Aiba T, Inagaki M, Kurita T, Suyama K, et al. Differential effects of beta-blockade on dispersion of repolarization in the absence and presence of sympathetic stimulation between the LQT1 and LQT2 forms of congenital long QT syndrome. J Am Coll Cardiol. 2002;39:1984-91.
104. Chatrath R, Bell CM, Ackerman MJ. Beta-blocker therapy failures in symptomatic probands with genotyped long-QT syndrome. Pediatr Cardiol. 2004;25:459-65.
105. Dorostkar PC, Eldar M, Belhassen B, Scheinman MM. Long-term follow-up of patients with long-QT syndrome treated with betablockers and continuous pacing. Circulation. 1999;100:2431-6.
106. Priori SG, Napolitano C, Schwartz PJ, Grillo M, Bloise R, Ronchetti E, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA. 2004;292:1341-4.
107. Moss AJ, Zareba W, Hall WJ, Schwartz PJ, Crampton RS, Benhorin J, et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation. 2000;101:616-23.
108. Benhorin J, Taub R, Goldmit M, Kerem B, Kass RS, Windman I, et al. Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome? Circulation. 2000;101:1698-706.
109. Schulze-Bahr E, Fenge H, Etzrodt D, Haverkamp W, Monnig G, Wedekind H, et al. Long QT syndrome and life threatening arrhythmia in a newborn: molecular diagnosis and treatment response. Heart. 2004;90:13-6.
110. Kehl HG, Haverkamp W, Rellensmann G, Yelbuz TM, Krasemann T, Vogt J, et al. Images in cardiovascular medicine. Life-threatening neonatal arrhythmia: successful treatment and confirmation of clinically suspected extreme long QT-syndrome-3. Circulation. 2004;109:e205-6.
111. Fredj S, Sampson KJ, Liu H, Kass RS. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. Br J Pharmacol. 2006;148:16-24.
112. Shimizu W, Kurita T, Matsuo K, Suyama K, Aihara N, Kamakura S, et al. Improvement of repolarization abnormalities by a K+ channel opener in the LQT1 form of congenital long-QT syndrome. Circulation. 1998;97:1581-8.
113. Etheridge SP, Compton SJ, Tristani-Firouzi M, Mason JW. A new oral therapy for long QT syndrome: long-term oral potassium improves repolarization in patients with HERG mutations. J Am Coll Cardiol. 2003;42:1777-82.
114. Khan IA, Gowda RM. Novel therapeutics for treatment of long-QT syndrome and torsade de pointes. Int J Cardiol. 2004;95:1-6.
115. Viskin S. Cardiac pacing in the long QT syndrome: review of available data and practical recommendations. J Cardiovasc Electrophysiol. 2000;11:593-600.
116. Moss AJ, Liu JE, Gottlieb S, Locati EH, Schwartz PJ, Robinson JL. Efficacy of permanent pacing in the management of high-risk patients with long QT syndrome. Circulation. 1991;84:1524-9.
117. Pinski SL, Eguia LE, Trohman RG. What is the minimal pacing rate that prevents torsades de pointes? Insights from patients with permanent pacemakers. Pacing Clin Electrophysiol. 2002;25:1612-5.
118. Monnig G, Kobe J, Loher A, Eckardt L, Wedekind H, Scheld HH, et al. Implantable cardioverter-defibrillator therapy in patients with congenital long-QT syndrome: a long-term follow-up. Heart Rhythm. 2005;2:497-504.
119. Zareba W, Moss AJ, Daubert JP, Hall WJ, Robinson JL, Andrews M. Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol. 2003;14:337-41.
120. Kaufman ES. Saving lives in congenital long QT syndrome: who benefits from implantable cardioverter defibrillator therapy? J Cardiovasc Electrophysiol. 2003;14:342-3.
121. Goel AK, Berger S, Pelech A, Dhala A. Implantable cardioverter defibrillator therapy in children with long QT syndrome. Pediatr Cardiol. 2004;25:370-8.
122. Moss AJ, McDonald J. Unilateral cervicothoracic sympathetic ganglionectomy for the treatment of long QT interval syndrome. N Engl J Med. 1971;285:903-4.
123. Schwartz PJ, Locati EH, Moss AJ, Crampton RS, Trazzi R, Ruberti U. Left cardiac sympathetic denervation in the therapy of congenital long QT syndrome. A worldwide report. Circulation. 1991;84:503-11.
124. Wang LX. Role of left cardiac sympathetic denervation in the management of congenital long QT syndrome. J Postgrad Med. 2003;49:179-81.
125. Wang L, Feng G. Left cardiac sympathetic denervation as the first-line therapy for congenital long QT syndrome. Med Hypotheses. 2004;63:438-41.
126. Schwartz PJ, Priori SG, Cerrone M, Spazzolini C, Odero A, Napolitano C, et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation. 2004;109:1826-33.
127. Haissaguerre M, Extramiana F, Hocini M, Cauchemez B, Jais P, Cabrera JA, et al. Mapping and ablation of ventricular fibrillation associated with long-QT and Brugada syndromes. Circulation. 2003;108:925-8.